Concomitant lung metastasis in patients with advanced hepatocellular carcinoma

Table 1 Baseline characteristics of hepatocellular carcinoma patients presenting with lung metastasis (mean ± SD) n (%)

	Total (n = 76)	Untreated group (n = 22)	Single treated group (n = 19)	Combined treated group (n = 35)	P value
Sex
Male	59 (77.6)	16 (72.7)	15 (78.9)	28 (80.0)	0.804
Female	17 (22.4)	6 (27.3)	4 (21.1)	7 (20.0)
Age (yr)	52.4 ± 10.7	52.8 ± 9.3	52.5 ± 11.6	52.1 ± 11.4	0.971
Etiology
HBV	63 (82.9)	18 (82.9)	16 (84.2)	29 (82.9)	0.989
HCV	3 (3.9)	1 (4.5)	1 (5.3)	1 (2.9)
Alcohol	5 (6.6)	1 (4.5)	1 (5.3)	3 (8.6)
Non-B and non-C	5 (6.6)	2 (9.1)	1 (5.3)	2 (5.7)
Cirrhosis	65 (85.5)	20 (90.9)	17 (89.5)	28 (80.0)	0.443
Platelet (-3)	185.8 ± 75.5	180.9 ± 95.1	174.3 ± 74.0	195.1 ± 62.6	0.593
Albumin (g/L)	36.5 ± 4.3	36.3 ± 5.4	35.3 ± 3.5	37.3 ± 3.7	0.276
ALT (IU/L), median (range)	35 (10-352)	35 (15-352)	37 (15-124)	34 (10-210)	0.456
AST (IU/L), median (range)	35 (16-453)	41 (16-453)	44 (20-173)	33 (17-223)	0.364
Total bilirubin (μmol/L)	23.7 ± 13.3	28.1 ± 17.4	23.3 ± 8.1	21.2 ± 12.2	0.162
Prothrombin time (s)	12.9 ± 1.7	13.3 ± 2.3	13.0 ± 1.3	12.5 ± 1.3	0.241
AFP (ng/mL)
< 400	36 (47.4)	10 (45.5)	7 (36.8)	19 (54.3)	0.461
≥ 400	40 (52.6)	12 (54.5)	12 (63.2)	16 (52.6)
ECOG score
0	17 (22.4)	4 (18.2)	4 (21.1)	9 (25.7)	0.672
1	54 (71.1)	16 (72.7)	15 (78.9)	23 (65.7)
2	5 (6.6)	2 (9.1)	0 (0)	3 (8.6)
Ascites
None	67 (88.2)	18 (81.8)	16 (84.2)	33 (94.3)	0.303
Mild–moderate	9 (11.8)	4 (18.2)	3 (15.8)	2 (5.7)
Child-Pugh score
A	61 (80.3)	16 (72.7)	14 (73.7)	31 (88.6)	0.243
B	15 (19.7)	6 (27.3)	5 (26.3)	4 (11.4)

HBV: Hepatitis B virus; HCV: Hepatitis C virus; ALT: Alanine transaminase; AST: Aspartate aminotransferase; AFP: Alpha-fetoprotein; ECOG: Eastern cooperative oncology group.